# Improving the Efficacy of Anti-Nicotine Immunotherapy

> **NCT01280968** · PHASE2 · COMPLETED · sponsor: **Alexey Mukhin** · enrollment: 52 (actual)

## Conditions studied

- Nicotine Dependence

## Interventions

- **BIOLOGICAL:** NIC002 in Aluminum hydroxide (Alum)
- **BIOLOGICAL:** Placebo Vaccine - Aluminum hydroxide

## Key facts

- **NCT ID:** NCT01280968
- **Lead sponsor:** Alexey Mukhin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-09
- **Final completion:** 2013-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280968, "Improving the Efficacy of Anti-Nicotine Immunotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01280968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*